Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses

被引：36

作者：

Curran, Rhonda M. ^{[1
]}

Donnelly, Louise ^{[1
]}

Morrow, Ryan J. ^{[1
]}

Fraser, Carol ^{[2
]}

Andrews, Gavin ^{[1
]}

Cranage, Martin ^{[2
]}

Malcolm, R. Karl ^{[1
]}

Shattock, Robin J. ^{[2
]}

Woolfson, A. David ^{[1
]}

机构：

[1] Queens Univ Belfast, Sch Pharm, Ctr Med Biol, Belfast BT9 7BL, Antrim, North Ireland

[2] St Georges Univ London, Div Cellular & Mol Med, Ctr Infect, London SW17 0RE, England

来源：

VACCINE | 2009年 / 27卷 / 48期

基金：

英国惠康基金;

关键词：

Vaginal delivery; Mucosal vaccination; HIV-1; GENITAL-TRACT; IN-VITRO; INTRAVAGINAL IMMUNIZATION; ANTIBODY-RESPONSE; ENHANCED MUCOSAL; VACCINE; MUCOADHESIVE; SYSTEMS; INFECTION; HIV/AIDS;

D O I：

10.1016/j.vaccine.2009.08.088

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Rheologically structured vehicle (RSV) gels were developed as delivery systems for vaginal mucosal vaccination with an HIV-1 envelope glycoprotein (CN54gp140). RSVs comprised a mucoadhesive matrix-forming and vaginal fluid absorbing polymer. The mucoadhesive and rheological properties of the RSVs were evaluated in vitro, and the distribution, antigenicity and release of CN54gp140 were analysed by ELISA. CN54gp140 was uniformly distributed within the RSVs and continuously released in vitro in an antigenically intact form over 24 h. Vaginal administration to rabbits induced specific serum IgG, and IgG and IgA in genital tract secretions. The RSVs are a viable delivery modality for vaginal immunization. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：6791 / 6798

页数：8

共 41 条

[1] Characterization of the Rheological, Mucoadhesive, and Drug Release Properties of Highly Structured Gel Platforms for Intravaginal Drug Delivery [J].

Andrews, Gavin P. ;

Donnelly, Louise ;

Jones, David S. ;

Curran, Rhonda M. ;

Morrow, Ryan J. ;

Woolfson, A. David ;

Malcolm, R. Karl .

BIOMACROMOLECULES, 2009, 10 (09) :2427-2435

[2]

[Anonymous], 2008 REPORT GLOBAL A

[3]

Balzarini J, 2007, LANCET, V369, P787, DOI 10.1016/S0140-6736(07)60202-5

[4] Effect of route of vaccination with vaccinia virus expressing HSV-2 glycoprotein D on protection from genital HSV-2 infection [J].

Bernstein, DI .

VACCINE, 2000, 18 (14) :1351-1358

[5] Development and in vitro evaluation of chloroquine gels as microbicides against HIV-1 infection [J].

Brouwers, Joachim ;

Vermeire, Kurt ;

Schols, Dominique ;

Augustijns, Patrick .

VIROLOGY, 2008, 378 (02) :306-310

[6]

Brown Larry R, 2005, Expert Opin Drug Deliv, V2, P29, DOI 10.1517/17425247.2.1.29

[7] HIV Prevention 3 - Behavioural strategies to reduce HIV transmission: how to make them work better [J].

Coates, Thomas J. ;

Richter, Linda ;

Caceres, Carlos .

LANCET, 2008, 372 (9639) :669-684

[8] Repeated vaginal administration of trimeric HIV-1 clade C gp140 induces serum and mucosal antibody responses [J].

Cranage, M. P. ;

Fraser, C. A. ;

Stevens, Z. ;

Huting, J. ;

Chang, M. ;

Jeffs, S. A. ;

Seaman, M. S. ;

Cope, A. ;

Cole, T. ;

Shattock, R. J. .

MUCOSAL IMMUNOLOGY, 2010, 3 (01) :57-68

[9] Development and evaluation of a thermoreversible ovule formulation of stampidine, a novel nonspermicidal broad-spectrum anti-human immunodeficiency virus microbicide [J].

D'Cruz, OJ ;

Samuel, P ;

Waurzyniak, B ;

Uckun, FM .

BIOLOGY OF REPRODUCTION, 2003, 69 (06) :1843-1851

[10]

ECKSTEIN P, 1969, J REPROD FERTIL, V20, P85

← 1 2 3 4 5 →